Carcinosarcoma of the prostate is a very rare malignant tumor in men. Only 4 cases have been reported in the English literature. We give herein the 5th case report of carcinosarcoma of the prostate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000472676 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dextran-Graft-Polyacrylamide/Zinc Oxide Nanoparticles Inhibit of Cancer Cells in vitro and in vivo.
Int J Nanomedicine
November 2024
Faculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Introduction: Tumor drug resistance and systemic toxicity are major challenges of modern anticancer therapy. Nanotechnology makes it possible to create new materials with the required properties for anticancer therapy.
Methods: In this research, Dextran-graft-Polyacrylamide/ZnO nanoparticles were used.
A case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant.
J Obstet Gynaecol Res
December 2024
Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Ovarian carcinosarcoma in hereditary breast and ovarian cancer syndrome is rare. A 43-year-old woman with a family history of prostate and uterine or ovarian cancer had an 8-cm mass in the right ovary. Although computed tomography suggested peritoneal dissemination to the Douglas pouch, she wanted to preserve her fertility; therefore, she underwent a right salpingo-oophorectomy.
View Article and Find Full Text PDFClinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S. An analysis of SEER database.
Can Urol Assoc J
November 2024
Mitchell Cancer Institute, University of South Alabama, Mobile, AL, United States.
Introduction: Prostatic carcinosarcoma comprises <1% of all prostate neoplasms. The literature on this disease is limited to a few case studies, primarily due to the rarity of this malignancy. We aimed to investigate the demographic, clinical, and histologic factors, prognosis, and survival of prostatic carcinosarcoma.
View Article and Find Full Text PDFAPOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Neurol Res
March 2024
Department of Neurosurgery, The affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Article Synopsis
- APOBEC type 3C (A3C) is identified as a potential cancer biomarker for lower-grade gliomas (LGGs), but its specific role in improving clinical outcomes through immunotherapy is still unclear.
- Research utilized RNA sequencing and bioinformatic analyses to find that A3C is expressed significantly higher in LGGs compared to normal tissues, making it an independent predictor for patient prognosis.
- The study also discovered that A3C is associated with immune cell infiltration and chemotherapy sensitivity, suggesting that targeting A3C could improve immunotherapy effectiveness for LGGs.
Immunological Role of Somatic Mutation Classification in Human Cancers.
J Oncol
February 2023
Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer(IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Background: is a very common tumor suppressor gene and has implicated in various cancers. A systematic immunological analysis of somatic mutation classification in multiple cancers is still lacking.
Methods: To assess the immunological value of somatic mutation classification in various cancers, we integrated a series of bioinformatics methods to analyze the role of gene across the public databases, such as UCSC Xena, Cancer Cell Line Encyclopedia (CCLE), Ensembl, and Genotype-Tissue Expression (GTEx).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!